Biomedicine & Pharmacotherapy SCIE

國(guó)際簡(jiǎn)稱：BIOMED PHARMACOTHER 參考譯名：生物醫(yī)學(xué)與藥物治療

主要研究方向：醫(yī)學(xué)-藥學(xué) 預(yù)警期刊審稿周期：約2月約7周

《生物醫(yī)學(xué)與藥物治療》(Biomedicine & Pharmacotherapy)是一本由Elsevier Masson出版的以醫(yī)學(xué)-藥學(xué)為研究特色的國(guó)際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開(kāi)放期刊。該期刊享有很高的科學(xué)聲譽(yù)，影響因子不斷增加，發(fā)行量也同樣高。

2區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
1743 年發(fā)文量
6.9 IF影響因子
未開(kāi)放 是否OA
78 H-index
1982 創(chuàng)刊年份
Monthly 出版周期
Multi-Language 出版語(yǔ)言

Biomedicine & Pharmacotherapy is a multidisciplinary journal which publishes full-length, original research reports, reviews, and preliminary communications or letters to the editor which fall within the general scope of clinical and basic medicine and pharmacology.

The general fields of interest will include Cancer, Nutriceutics, Neurodegenerative, Cardiac and Infectious Diseases.

Special emphasis will be placed on studies of specific topics such as molecular mechanisms, gene regulation in normal and pathologic cells as well as susceptibility in response to oncogenic agents. Effects of drugs on preclinical and clinical pharmacology and the role of bacteria, viruses and parasites in animals and humans.

Brief reports of meetings, symposia and conferences will also be considered for publication as well as brief listings of scientific meetings or academic courses of interest to the readers

[ 查看全部 ]

投稿咨詢加急咨詢

Biomedicine & Pharmacotherapy期刊信息

ISSN：0753-3322
出版語(yǔ)言：Multi-Language
是否OA：未開(kāi)放
E-ISSN：1950-6007
出版地區(qū)：FRANCE
是否預(yù)警：是
出版商：Elsevier Masson
出版周期：Monthly
創(chuàng)刊時(shí)間：1982
開(kāi)源占比：0.9507
Gold OA文章占比：96.76%
OA被引用占比：0.5432...
出版國(guó)人文章占比：0.56
出版撤稿占比：0.0061...
研究類文章占比：67.58%

Biomedicine & Pharmacotherapy CiteScore評(píng)價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

11.9

1.493

1.409

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q1	28 / 313	91%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評(píng)論、會(huì)議論文、書(shū)籍章節(jié)和數(shù)據(jù)論文。

Biomedicine & Pharmacotherapy中科院評(píng)價(jià)數(shù)據(jù)

中科院 2023年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	2區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn)	1區(qū) 2區(qū)

中科院 2022年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	2區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn)	1區(qū) 2區(qū)

中科院 2021年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	2區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn)	1區(qū) 2區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	2區(qū)	MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn) PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū) 2區(qū)

中科院 2021年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	2區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn)	1區(qū) 2區(qū)

中科院 2020年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	2區(qū)	MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn) PHARMACOLOGY & PHARMACY 藥學(xué)	2區(qū) 2區(qū)

Biomedicine & Pharmacotherapy JCR評(píng)價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q1	21 / 189	89.2%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	15 / 354	95.9%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q1	18 / 189	90.74%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	25 / 354	93.08%

Biomedicine & Pharmacotherapy歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Biomedicine & Pharmacotherapy中國(guó)學(xué)者發(fā)文選摘

1、Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective virus replication and CD8+T cell-dependent immune response
Author: Liu, Jing; Hu, Yan-Yan; Zhang, Qiu-Yan; Zhang, Ya-Nan; Li, Na; Zhang, Zhe-Rui; Zhan, Shun-Li; Gao, Lei; Deng, Cheng-Lin; Li, Xiao-Dan; Yuan, Shao-Peng; He, Yuan-Qiao; Ye, Han-Qing; Zhang, Bo

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114094
2、Glutathione improves testicular spermatogenesis through inhibiting oxidative stress, mitochondrial damage, and apoptosis induced by copper deposition in mice with Wilson disease
Author: Chen, Kuiyu; Wu, Limin; Liu, Qianzhuo; Tan, Fang; Wang, Luyao; Zhao, Dan; Fang, Xinru; Liu, Xiang; Liu, Jiabo; Han, Hui

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114107
3、Arctium lappa (Burdock): Insights from ethnopharmacology potential, chemical constituents, clinical studies, pharmacological utility and nanomedicine
Author: Yosri, Nermeen; Alsharif, Sultan M.; Xiao, Jianbo; Musharraf, Syed G.; Zhao, Chao; Saeed, Aamer; Gao, Ruichang; Said, Noha S.; Di Minno, Alessandro; Daglia, Maria; Guo, Zhiming; Khalifa, Shaden A. M.; El-Seedi, Hesham R.

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114104
4、A novel inhibitor of PGK1 suppresses the aerobic glycolysis and proliferation of hepatocellular carcinoma
Author: Li, Mingfeng; Zhang, Aotong; Qi, Xin; Yu, Rilei; Li, Jing

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114115
5、Sodium tanshinone IIA sulfonate protects against hyperhomocysteine-induced vascular endothelial injury via activation of NNMT/SIRT1-mediated NRF2/HO-1 and AKT/MAPKs signaling in human umbilical vascular endothelial cells
Author: Zhou, Zhong-Yan; Shi, Wen-Ting; Zhang, Jing; Zhao, Wai-Rong; Xiao, Ying; Zhang, Kai-Yu; Ma, Jie; Tang, Jing-Yi; Wang, Yu

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114137
6、Attenuation of hyperglycemia-associated dyslipidemic, oxidative, cognitive, and inflammatory crises via modulation of neuronal ChEs/NF-kappa B/COX-2/NOx, and hepatorenal functional deficits by the Tridax procumbens extract
Author: Hogan, Itam Ako; Kuo, Yu-Cheng; Abubakar, Asmau N.; Lawal, Bashir; Agboola, Abdulhakeem R.; Lukman, Halimat Yusuf; Onikanni, Sunday Amos; Olawale, Femi; Fadaka, Adewale Oluwaseun; Ibrahim, Yunusa O.; Babalola, Shukurat B.; Batiha, Gaber El -Saber; Albogami, Sarah M.; Alorabi, Mohammed; De Waard, Michel; Huang, Hsu-Shan

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114114
7、Exercise induced meteorin-like protects chondrocytes against inflammation and pyroptosis in osteoarthritis by inhibiting PI3K/Akt/NF-kappa B and NLRP3/caspase-1/GSDMD signaling
Author: Liu, Jiabao; Jia, Shuangshuo; Yang, Yue; Piao, Longhuan; Wang, Ziyuan; Jin, Zhuangzhuang; Bai, Lunhao

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114118
8、Revealment study on the regulation of lipid metabolism by Lingguizhugan Decoction in heart failure treatment based on integrated lipidomics and proteomics
Author: Wang, Xu; Gao, Yanhua; Zhang, Jia; Zhang, Huaxing; Sun, Shuo; Su, Suwen; Kong, Dezhi; Wang, Qiao

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114066